Multiple System Atrophy clinical trials

The registry lists 207 studies for Multiple System Atrophy across more than 10 countries. 73 are recruiting or about to start. 89 of them are mainly about Multiple System Atrophy (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-09. Counting its narrower condition Shy-Drager Syndrome too: 230 studies, 83 open.

Get an email when these change. Save the Multiple System Atrophy studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Watch these studies

See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your saved searches, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your saved searches. Stop any time.

Status

Completed: 89
Recruiting: 57
Active, not recruiting: 16
Terminated: 14
Status unknown: 11
Enrolling by invitation: 7

Phase

Phase 2: 35
Phase 1: 27
Phase 3: 15
Early Phase 1: 11
Phase 4: 3

Where

United States: 90
France: 32
China: 26
Italy: 21
United Kingdom: 19
Germany: 13

Who runs them

Vanderbilt University (9) · Vanderbilt University Medical Center (9) · University Hospital, Bordeaux (8) · University Hospital, Toulouse (6) · MODAG GmbH (5) · NYU Langone Health (5) · Alterity Therapeutics (4) · National Institute of Neurological Disorders and Stroke (NINDS) (4)

What is being tested here

Drugs under test in Multiple System Atrophy studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug	Open	Phase 3	All
ALT001	2	0	2
ATH434	1	0	3
ONO-2808	1	1	2
Tributyrin	1	0	1
Butylphthalide	1	1	1
Fluorodopa F 18	1	0	1
Nicotinamide-beta-riboside	1	0	1
Droxidopa	0	4	8
Midodrine	0	0	3
AZD3241	0	1	3

Coming up

4phase 3 studies under way

36studies finish main data collection within a year1 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Apr 2027Efficacy and Safety of Butylphthalide in the Treatment of Multiple System Atrophy · Phase 3 · Second Affiliated Hospital, Zhejiang University, School of Medicine
Nov 2026PET Imaging Evaluation of [11C]SY08 · Massachusetts General Hospital
Nov 2026Overnight Trials With Heat Stress in Autonomic Failure Patients With Supine Hypertension · Vanderbilt University Medical Center
Dec 2026Randomized Double-Blind Placebo-Controlled Adaptive Design Trial Of Intrathecally Administered Autologous Mesenchymal Stem Cells In Multiple System Atrophy · Mayo Clinic
Dec 2026Reduction in Splanchnic Capacitance Contributes to Sympathetically Dependent Hypertension in Autonomic · Vanderbilt University
Dec 2026[18F]ACI-15916 PET in α-synucleinopathies · AC Immune SA
Dec 2026A Study to Evaluate Satety, Tolerability, Biodistribution, Radiation Dosimetry, and Pharmacokinetics of SST001 in Healthy Volunteers, Patients With PD and Patients With MSA · Synusight Biotech (Shanghai) Co., Ltd.
Dec 2026Treatment of Supine Hypertension in Autonomic Failure (CPAP) · Vanderbilt University Medical Center
Dec 2026Natural History Study of Synucleinopathies · NYU Langone Health
Dec 2026A Prospective Exploratory Study of the Safety and Preliminary Efficacy of the α-Syn H21 Monoclonal Antibody in Patients With Multiple System Atrophy · Ruijin Hospital

Who these studies take

Of the 57 Multiple System Atrophy studies recruiting now, 24 (42%) set no upper age limit and 11 (19%) stop at 75 or younger. 7 (12%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 18 (32%) take healthy volunteers.

Recruiting studies that take each age, of 57
Age	Women	Men
10	6 (11%)	6 (11%)
18	23 (40%)	23 (40%)
30	39 (68%)	39 (68%)
40	49 (86%)	49 (86%)
50	57 (100%)	57 (100%)
65	56 (98%)	56 (98%)
75	53 (93%)	53 (93%)
85	31 (54%)	31 (54%)

Across all 207 studies, recruiting or not: 19% stop at 75 or younger and 2% at 65; 10% take children; 0% are for women only and 0% for men only; 29% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Multiple System Atrophy studies take

Of 25 phase 1 interventional studies under Multiple System Atrophy, half reached primary completion within 28 months of starting, counting those still running.

Start to primary completion	Every sponsor	Industry	Non-industry
Phase 1	28 mo20–55 · 25 studies	—	—
Phase 2	23 mo16–32 · 19 studies	—	—
Interventional, no phase	38 mo24–71 · 43 studies	—	38 mo24–71 · 42 studies
Observational	94 mo37–… · 39 studies	—	—

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 11, 2026.

Started recruiting1

Efficacy and Safety of Butylphthalide in the Treatment of Multiple System AtrophyOct 16, 2026NCT07518810

Stopped1

Effects of Midodrine and Droxidopa on Splanchnic Capacitance in Autonomic FailureTerminatedOct 23, 2026NCT02897063

Studies

Recruiting first, then most recently updated. Showing 50 of 207. Browse all 207 → or search them.